Andersen-Tawil syndrome classification: Difference between revisions

Jump to navigation Jump to search
Line 16: Line 16:
OR
OR


Andersen–Tawil syndrome may be classified according to genetic mutations into two groups:<ref name="pmid24383070">{{cite journal| author=Nguyen HL, Pieper GH, Wilders R| title=Andersen-Tawil syndrome: clinical and molecular aspects. | journal=Int J Cardiol | year= 2013 | volume= 170 | issue= 1 | pages= 1-16 | pmid=24383070 | doi=10.1016/j.ijcard.2013.10.010 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24383070  }}</ref><ref name="pmid20306271">{{cite journal| author=Tristani-Firouzi M, Etheridge SP| title=Kir 2.1 channelopathies: the Andersen-Tawil syndrome. | journal=Pflugers Arch | year= 2010 | volume= 460 | issue= 2 | pages= 289-94 | pmid=20306271 | doi=10.1007/s00424-010-0820-6 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20306271  }}</ref>
Andersen–Tawil syndrome may be classified according to genetic mutations into two groups:<ref name="pmid24383070">{{cite journal| author=Nguyen HL, Pieper GH, Wilders R| title=Andersen-Tawil syndrome: clinical and molecular aspects. | journal=Int J Cardiol | year= 2013 | volume= 170 | issue= 1 | pages= 1-16 | pmid=24383070 | doi=10.1016/j.ijcard.2013.10.010 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24383070  }}</ref><ref name="pmid20306271">{{cite journal| author=Tristani-Firouzi M, Etheridge SP| title=Kir 2.1 channelopathies: the Andersen-Tawil syndrome. | journal=Pflugers Arch | year= 2010 | volume= 460 | issue= 2 | pages= 289-94 | pmid=20306271 | doi=10.1007/s00424-010-0820-6 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20306271 }}</ref><ref name="pmid17395133">{{cite journal| author=Sansone V, Tawil R| title=Management and treatment of Andersen-Tawil syndrome (ATS). | journal=Neurotherapeutics | year= 2007 | volume= 4 | issue= 2 | pages= 233-7 | pmid=17395133 | doi=10.1016/j.nurt.2007.01.005 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17395133 }}</ref>


<br />
<br />

Revision as of 17:44, 28 January 2020

Andersen-Tawil syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Differentiating Andersen-Tawil syndrome from other Diseases

Epidemiology and Demographics

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Tertiary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Andersen-Tawil syndrome classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

slides

Images

American Roentgen Ray Society Images of Andersen-Tawil syndrome classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Andersen-Tawil syndrome classification

CDC on Andersen-Tawil syndrome classification

Andersen-Tawil syndrome classification in the news

Blogs on Andersen-Tawil syndrome classification

Directions to Hospitals Treating Andersen-Tawil syndrome

Risk calculators and risk factors for Andersen-Tawil syndrome classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Charmaine Patel, M.D. [2]; Raviteja Guddeti, M.B.B.S. [3]

Overview

Andersen–Tawil syndrome may be classified according to genetic mutations into two groups: Type 1 Andersen–Tawil syndrome and type 2 Andersen–Tawil syndrome


  • Type 1, which accounts for about 60 percent of all cases of the disorder, is caused by mutations in the KCNJ2 gene. [1][2]
  • The remaining 40 percent of cases are designated as type 2; the cause of the condition in these cases is unknown.

Classification

There is no established system for the classification of [disease name].

OR

Andersen–Tawil syndrome may be classified according to genetic mutations into two groups:[3][4][5]


Type Gene involved Protein involved Location Inheritance pattern
Andersen–Tawil syndrome (ATS) 1 KCNJ2 gene (60%) Kir2.1 inward rectifier potassium channel 17q24.3 Autosomal dominant
Andersen–Tawil syndrome (ATS) 2 Unknown gene defect (40%) Kir2.1 inward rectifier potassium channel 17q24.3 Autosomal dominant

[Disease name] may be classified into [large number > 6] subtypes based on:

  • [Classification method 1]
  • [Classification method 2]
  • [Classification method 3]

[Disease name] may be classified into several subtypes based on:

  • [Classification method 1]
  • [Classification method 2]
  • [Classification method 3]

References

  1. Tristani-Firouzi M, Jensen JL, Donaldson MR; et al. (2002). "Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome)". J. Clin. Invest. 110 (3): 381–8. PMID 12163457.
  2. Pegan S, Arrabit C, Slesinger PA, Choe S (2006). "Andersen's syndrome mutation effects on the structure and assembly of the cytoplasmic domains of Kir2.1". Biochemistry. 45 (28): 8599–606. doi:10.1021/bi060653d. PMID 16834334.
  3. Nguyen HL, Pieper GH, Wilders R (2013). "Andersen-Tawil syndrome: clinical and molecular aspects". Int J Cardiol. 170 (1): 1–16. doi:10.1016/j.ijcard.2013.10.010. PMID 24383070.
  4. Tristani-Firouzi M, Etheridge SP (2010). "Kir 2.1 channelopathies: the Andersen-Tawil syndrome". Pflugers Arch. 460 (2): 289–94. doi:10.1007/s00424-010-0820-6. PMID 20306271.
  5. Sansone V, Tawil R (2007). "Management and treatment of Andersen-Tawil syndrome (ATS)". Neurotherapeutics. 4 (2): 233–7. doi:10.1016/j.nurt.2007.01.005. PMID 17395133.


Template:WikiDoc Sources CME Category::Cardiology